We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Inclisiran (Leqvio) — PCSK9-targeting siRNA
A small interfering RNA (siRNA) prescription drug (Leqvio) that silences PCSK9 in the liver, cutting LDL cholesterol ~50%. Distinctive for being dosed by subcutaneous injection only twice a year after the first doses — a major adherence advantage. LDL lowering is well established (ORION-9/-10/-11); cardiovascular-outcome benefit is NOT yet proven (ORION-4/VICTORION trials ongoing). Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Inclisiran (Leqvio) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Inclisiran (Leqvio) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2017–2027 with a typical study size of 3,660 participants.
Based on 116 studies · 19 meta-analyses · 32 RCTs · 4,042 total participants
Confidence
High confidenceBy outcome
Inclisiran produces strong, durable ~50% LDL-cholesterol reductions across a well-conducted phase 3 program (ORION-9/-10/-11) with a twice-yearly dosing advantage, but cardiovascular-outcome benefit — actual reductions in heart attacks, strokes, and CV death — is not yet proven (ORION-4/VICTORION ongoing), so the overall evidence stays Moderate.
29 randomised trials
90% were about Inclisiran (Leqvio) in an audit of 29 of them
Every randomised or controlled trial of Inclisiran (Leqvio) indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
6 trials ongoing or recruiting · 5 completed on ClinicalTrials.gov
Registered trials show research momentum for Inclisiran (Leqvio), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Inclisiran is a GalNAc-conjugated small interfering RNA (siRNA) that lowers LDL cholesterol by silencing PCSK9 messenger RNA inside hepatocytes.
The GalNAc sugar targets the molecule to liver cells, where the RNA-interference machinery degrades PCSK9 mRNA — so the liver makes less PCSK9, more LDL receptors stay on the cell surface, and more LDL is cleared from the blood.
It is a fundamentally different approach from statins (which block cholesterol synthesis) and from the PCSK9 monoclonal antibodies evolocumab and alirocumab (which mop up the PCSK9 protein after it is made); inclisiran shuts off production upstream.
The headline distinction is dosing: after an initial dose and one at day 90, inclisiran is given as a subcutaneous injection only twice a year (every 6 months), versus daily statins or fortnightly/monthly antibody injections — a potentially large real-world adherence advantage.
The pivotal phase 3 program (ORION-9 in heterozygous familial hypercholesterolemia, ORION-10 and ORION-11 in atherosclerotic cardiovascular disease / high risk) showed sustained placebo-corrected LDL-C reductions of roughly 48–52% maintained across the dosing interval, and the 4-year ORION-3 open-label extension showed the effect is durable with repeated dosing.
The honest limitation: those are LDL-lowering (surrogate) outcomes. Whether inclisiran actually reduces heart attacks, strokes, and cardiovascular death — the way statins and the PCSK9 antibodies have been shown to — is still unproven, with the cardiovascular-outcomes trials (ORION-4 and the VICTORION program) ongoing.
It is generally well tolerated; the most characteristic adverse effect is injection-site reactions (transient pain, redness, or a hardened area).
It is an expensive prescription drug administered by a clinician, not a supplement, and the score reflects strong, durable LDL-lowering evidence set against pending cardiovascular-outcome data and cost.
A small interfering RNA that engages the RNA-interference machinery to degrade PCSK9 messenger RNA in liver cells, so less PCSK9 protein is made.
A triantennary GalNAc sugar conjugate binds the asialoglycoprotein receptor, delivering the siRNA selectively into hepatocytes — enabling low, infrequent subcutaneous dosing.
Less PCSK9 means more LDL receptors recycle to the cell surface, clearing more LDL cholesterol from the blood — lowering LDL-C by roughly half.
How Inclisiran (Leqvio) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Data are limited; avoid unless a clinician judges benefit to outweigh unknown risk.
Limited data in severe impairment; use under specialist supervision.
Be aware that inclisiran's outcome benefit is unproven; statins and PCSK9 antibodies have demonstrated event reduction.
Commonly and intentionally co-administered (additive LDL lowering); not a harmful interaction but combined lipid lowering should be clinician-monitored.
Redundant mechanism (both lower PCSK9 activity); combining is not standard and offers no established added benefit.
Tip: Usually transient and mild; rotate injection sites (abdomen, arm, thigh).
Tip: Generally self-limited; report persistent symptoms to your clinician.
Tip: Seek care for rash, swelling, or breathing difficulty after injection.
Inclisiran (Leqvio) has an evidence score of 4.1/10 — emerging evidence based on 116 indexed studies, including 2 meta-analyses. A small interfering RNA (siRNA) prescription drug (Leqvio) that silences PCSK9 in the liver, cutting LDL cholesterol ~50%. Distinctive for being dosed by subcutaneous injection only twice a year after the first doses — a major adherence advantage. LDL lowering is well established (ORION-9/-10/-11); cardiovascular-outcome benefit is NOT yet proven (ORION-4/VICTORION trials ongoing). Prescription drug, not a supplement. Representative study: PMID 33663735.
The commonly studied dose of Inclisiran (Leqvio) is 284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Inclisiran (Leqvio) — consistent daily use matters more than the time of day. A twice-yearly clinician-administered subcutaneous injection; timing relative to meals or time of day is not relevant.
Inclisiran (Leqvio) has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include hypersensitivity reaction, injection-site reaction (pain, redness, induration), arthralgia / limb pain. How often they occur is not established for all of them. Use caution if any of these apply to you: Known hypersensitivity to inclisiran or excipients; Not a substitute for a clinician's evaluation — prescription drug only.
Pioglitazone (Actos)
Too few graded studiesAn oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 116 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research